Cyclosporine in dermatology.
The entry of Cs into dermatology has been remarkable. It is too soon to say that the consequences will be revolutionary, but if the drug continues with its present promise and if toxicity does not prove a problem it could indeed promote a therapeutic revolution. In addition to this, Cs is likely to induce many new thoughts about possible mechanisms in dermatology and perversely in immunology, especially if it transpires that the mechanism of action of the drug is local and on an effector pathway. Thus it is too soon to predict what might be the place for Cs in dermatology. For the moment it is clear that there is an immense area in which a good deal of work has to be done to know whether the drug will fulfill its very great promise and the further prospect too that new analogues and topical preparations may take the therapeutic possibilities even further.
Shuster
S
S
Department of Dermatology, University of Newcastle upon Tyne, UK.
D003524:Cyclosporins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003872:Dermatitis / Q000188:drug therapy; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*
D003524:Cyclosporins